This product has received regulatory approval from the Drug Controller General of India (DCGI) following rigorous review and bioequivalence studies
Akums Drugs and Pharmaceuticals announces the launch of a room temperature stable oral suspension of Hydroxyurea. This formulation, designed to manage SCD, eliminates the need for cold storage, thereby enhancing accessibility and affordability for SCD patients nationwide.
Under the leadership of Health Minister Mansukh Mandviya and with guidance from a member of NITI Aayog, Dr V K Paul , Akums has achieved this milestone. This innovative product is accompanied by oral syringes for precise dosage administration for pediatrics, adolescents and adults.
Sanjeev Jain, Joint Managing Director of Akums Drugs and Pharmaceuticals, expressed, “Akums is passionately committed to advancing a noble cause and ensuring accessibility to affordable medication for SCD patients. In alignment with the objectives outlined in the National Sickle Cell Anemia Mission, as announced by the Honorable Prime Minister, Shri Narendra Modi Ji, Akums pledges to provide this innovative medicine at an affordable cost.”
Sandeep Jain, Joint Managing Director of Akums Drugs and Pharmaceuticals, affirmed, “We are dedicated to supporting the ‘Make in India’ initiative by researching high-quality pharmaceuticals. We aspire to make available the Hydroxyurea Oral Suspension, manufactured at a dedicated facility, to the government at less than 1 per cent of the cost of the global brand imported in India, ensuring equitable access to life-saving medication for all SCD patients.”
This product has received regulatory approval from the Drug Controller General of India (DCGI) following rigorous review and bioequivalence studies.
In contrast to the current import price of approximately Rs 77,000 for the global brand of Hydroxyurea solution, which necessitates storage at 2 to 8 degrees Celsius, Akums has innovated a room temperature stable oral suspension of Hydroxyurea suitable for Indian patients’ requirements.